M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
45 deals · US$6.8bndisclosed · Pharma Services · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Nov 2025 | Momentum Clinical Research | – | – | Merger | Completed | – | Clinical Trial Services+1 | Harmos Horton Lusk |
| 2026 | Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) | – | ACS Dobfar | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Lincoln International (sell-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Jan 2026 | Hayden Consulting Group | – | BGB Group | Acquisition | Completed | – | Pharma Services+2 | Morgan Lewis (sell-side)Clearsight Advisors (sell-side) |
| Jan 2026 | SubjectWell | – | – | Merger | Announced | – | Clinical Trial Services | Stout (sell-side)Fairmount Partners (buy-side) |
| Feb 2026 | Broth | – | Supreme Group | Acquisition | Announced | – | Advertising and marketing+1 | Edgemont Partners (sell-side) |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Announced | – | Pharma Services+2 | Goodwin (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| Mar 2026 | UK Biocentre | – | Azenta UK | Acquisition | Completed | 26.9 | Life Sciences+1 | Deloitte (buy-side)Bird & Bird (buy-side) |
| Mar 2026 | Owen Mumford Holdings | – | Embecta Corp. | Acquisition | Pending | 132.2 | Medtech+1 | Forvis Mazars (South Africa) (sell-side)Mills & Reeve (sell-side)J.P. Morgan (buy-side)A&O Shearman (buy-side) |
| Mar 2026 | Syntegon | CVC Capital Partners | Apollo | Stake | Announced | – | Manufacturing+2 | Willkie Farr & Gallagher (sell-side)Sidley Austin (buy-side) |
| Apr 2026 | Accessus Health | shareholders of Ecker + Ecker and Accessus Health | Athagoras | Acquisition | Announced | – | Accounting, legal and consulting+2 | Latham & Watkins (sell-side) |
| Apr 2026 | Modersys (fka SmartFactory Rx) | Applied Materials | TELEO Capital | Asset sale | Completed | – | Industrial Software+1 | Lazard |
| Apr 2026 | Celerion | H.I.G. Capital affiliate | THL Partners | Acquisition | Announced | – | Pharma Services+2 | LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side) |
| Apr 2026 | EpiVax | – | SV Health Investors | Acquisition | Announced | – | Pharma Services+2 | Morgan Lewis (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| May 2026 | CDMO and Cell Solutions businesses of Charles River Laboratories | Charles River Laboratories International | GI Partners | Asset sale | Completed | – | Pharma Services+2 | Moelis & Company (buy-side)Ropes & Gray (buy-side) |
| May 2026 | MacroGenics GMP manufacturing site and CDMO operations | MacroGenics | Bora Pharmaceuticals Co. | Asset sale | Completed | 122.5 | Pharmaceutical Manufacturing+1 | Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side) |
| May 2026 | AmbioPharm | – | CordenPharma | Acquisition | Announced | – | Pharma Services+2 | Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side) |
| Jun 2026 | Simbec-Orion | CBPE | – | Merger | Announced | – | Pharma Services+1 | Sidley AustinEdgemont Partners |
| Jul 2026 | Gerresheimer global Primary Packaging Plastics business | Gerresheimer AG | Apax Partners | Asset sale | Announced | 1,740.5 | Packaging+2 | Latham & Watkins (sell-side)Sullivan & Cromwell (buy-side) |
| Jul 2026 | InfoRLife SA | Sergio Dusci | BC Partners | Stake | Announced | – | Pharma Services+1 | Latham & Watkins (buy-side) |
| Jul 2026 | Commissioning Agents | – | JLL Partners | Acquisition | Completed | – | Pharma Services+1 | Stout (sell-side) |
| Jul 2026 | OptiMed Health Partners | – | Lee Equity Partners | Stake | Completed | – | Pharma Services+1 | Edgemont Partners (sell-side) |
| Jul 2026 | Asembia | – | Peak Rock Capital | Acquisition | Completed | – | Pharma Services+2 | BofA Securities (sell-side)McDermott Will & Schulte (sell-side)Kirkland & Ellis (buy-side)Houlihan Lokey (buy-side)Bass, Berry & Sims (buy-side) |
| Jul 2026 | Lannett | – | Aurobindo | Acquisition | Completed | 250.0 | Pharma+1 | Raymond JamesSullivan & Cromwell (buy-side) |
| Jul 2026 | PANTHERx Rare | Nautic Partners | Warburg Pincus-led investor group | Acquisition | Announced | – | Healthcare Services+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Ropes & Gray (sell-side)J.P. Morgan (buy-side)Cleary Gottlieb Steen & Hamilton (buy-side) |
| Jul 2026 | PolyPeptide Group AG | – | Samsung Biologics Co. | Acquisition | Announced | 1,454.0 | Pharma Services+2 | J.P. Morgan (buy-side)EY (buy-side)O'Melveny & Myers (buy-side)Schellenberg Wittmer (buy-side) |
| Aug 2026 | Relevate Health | Mountaingate Capital | – | Acquisition | Completed | – | Pharma Services+2 | Latham & Watkins (sell-side) |
| Aug 2026 | assets, business operations and customer relationships | – | NueCell Bio | Asset sale | Announced | – | Pharma Services+1 | Goodwin (buy-side) |
| Aug 2026 | MAIN5 | – | Astrix | Acquisition | Announced | – | Pharma Services+1 | Gibson Dunn (buy-side) |
| Aug 2026 | ZEPHYRx | – | a Leading Global CRO | Acquisition | Completed | – | Healthcare Software+1 | Morgan Lewis (sell-side)Edgemont Partners (sell-side) |
| Aug 2026 | Precision Medicine Group | Blackstone | McKesson | Acquisition | Announced | 2,250.0 | Clinical Trial Services+1 | Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side) |
| Sep 2026 | New Zealand Clinical Research Group (NZCR) | – | Advent | Acquisition | Announced | – | Clinical Trial Services | Cameron Partners (buy-side) |
| Sep 2026 | portfolio of 20 mature medicines and three manufacturing sites | Sanofi | Cheplapharm | Asset sale | Announced | – | Pharma+1 | Freshfields (sell-side)Latham & Watkins (buy-side) |
| Sep 2026 | Ambit RD | – | Danforth Health | Acquisition | Announced | – | Pharma Services+1 | Clearsight Advisors (sell-side) |
| Sep 2026 | Firma Data Services | Firma Clinical Research | Everest Clinical Research | Asset sale | Completed | – | Clinical Trial Services+1 | Edgemont Partners (sell-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Sep 2026 | Prolytix | Edgewater | VION | Acquisition | Announced | – | Pharma Services+1 | Stout (sell-side) |
| Sep 2026 | MLM Medical Labs | – | Labcorp | Acquisition | Announced | – | Clinical Trial Services+1 | William BlairEvercore (buy-side)Pierson Ferdinand (buy-side)Hogan Lovells Cadwalader (buy-side) |
| Sep 2026 | Lifecore Biomedical | – | Webster Equity Partners | Acquisition | Announced | 663.7 | Pharma Services+2 | Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.